1.5m loss for quarter plus a fresh 2.5m facility. You were wrong by a fair margin. What assumptions did you get wrong? Thanks
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%